Results | Latest & Breaking News on Results | Photos, Videos, Breaking Stories and Articles on Results- Moneycontrol

At Moneycontrol, the Results page helps you effectively track corporate announcements and results for various listed companies across both India and abroad. With our Results page, you can keep abreast with an updated, comprehensive view of all the profit/loss statements, company spendings, AGM outcomes, and quarterly and annual results from all these listed companies. Additionally, Moneycontrol also regularly tracks international MNCs listed on NASDAQ and Asian bourses, including popular companies like Apple, Google, Alibaba. Apart from finding solid copies of company results, stock movements consequent to these company results, expectations, and analytical post results copies, you will also find copies and articles detailing the earnings, impact, and all major announcements made to media/exchanges by these companies, so that you do not miss anything. We also provide you with concrete data points to help you spot profitable trades, stock build-ups, and bulk deals. At Moneycontrol, we also cover analysts/investors meetings; scrutinise results and data and BSE/NSE reports or news. The copies are not just full of information and data, but are also adequately supplemented with expert views, investor opinions, extensive interviews, videos, and a huge variety of explainers, analyses, and informative slideshows to help you gauge the market and make investment decisions in the best possible manner. More

Jump to

Divis Q1 PAT seen down 18.9% to Rs 261.4 cr: Edelweiss

Net Sales are expected to decrease by 15.1 percent Q-o-Q (up 15.0 percent Y-o-Y) to Rs 929.9 crore, according to Edelweiss
Divis Labs Q4 net seen up 10%, generic biz may support topline

Topline growth may be on the back of increased capacity utilisation at new SEZ units and generic business. Analysts feel capacity utilisation rates should rise to 80 percent against 75 percent earlier.
Divis Labs Q3 profit seen up 26% on strong EBITDA, revenue

Operating profit in Q3 is likely to jump 28.2 percent to Rs 364 crore and margin may expand 240 basis points to 38.4 percent compared to year-ago period.
Muted earnings growth likely in Q1FY14: Nirmal Bang

Nirmal Bang research expects the companies in their coverage universe to post a 4.4% YoY revenue growth, a 1% decline in EBITDA and a 7.2% fall in net profit. The performance reflects demand slowdown in the economy amid a depreciating Indian rupee.
Advertisement
Remove Ad
Advertisement
Remove Ad
Advertisement
Remove Ad
Advertisement
Remove Ad
Here's how to play Tech Mahindra, Voltas, Divis Lab post Q4

Sandeep Shenoy of Anand Rathi is bullish on Tech Mahindra and expects the company to perform well ahead. He recommends buying Divis Labs on dips.
Pharma cos likely to post 21% EBITDA growth in Q4: MOST

Motilal Oswal has come with its March`13 quarterly earning estimates for healthcare sector. The research firm expects a top line growth of 17.4% YoY and EBITDA growth of 21.3% YoY for our pharma universe (excluding one-offs).
Good performance likely from pharma in Q3: Nirmal Bang

Nirmal Bang has come out with its earnings estimates for pharmaceutical sector for the quarter ended December 2012. The research firm feels margins of pharma companies may witness YoY expansion owing to rupee depreciation (6 percent YoY).
See pharma sector's Q3 topline to grow 22%: Motilal Oswal

Motilal Oswal has come out with its earnings estimates for pharmaceuticals sector for the quarter ended December 2012. The research firm expects the topline to grow by 22 percent, EBITDA by 21 percent on the back of strong operational performance by Ranbaxy, Glenmark, Strides, Torrent and Divi's.
Advertisement
Remove Ad
See pharma sector's Q3 adj PAT to grow 26% YoY: P Lilladher

Prabhudas Lilladher has come out with its earnings estimates for pharmaceuticals sector for the quarter ended December 2012. The research firm expects top-line growth of 24 percent YoY for its coverage universe (excluding one-offs), with EBITDA growth at a robust 24 percent YoY.
Earnings watch: Which pharma co is in pink of its health?

In an interview to CNBC-TV18 Bino Pathiparampil of IIFL shared his expectation from various pharmaceutical companies ahead for their earnings.
Q3 earnings: Nirmal Bang reviews Glenmark, Divi's results

In an interview to CNBC-TV18, Praful Borah of Nirmal Bang Institutional Equities speak about Glenmark, Divi's results and gives his outlook going forward.
Pharma Q3: New launches, generic drug demand to aid growth

Pharmaceutical companies are expected to report healthy 15-25% year-on-year revenue growth in the third quarter, helped by new launches especially in the US and strong demand for generic drugs.
Advertisement
Remove Ad
Pharmaceutical results preview for Q3FY12: Emkay

Emkay Global Financial Services has come with its December quarterly earning estimates for pharmaceutical sector. According to the research firm the sector is expected to report a growth of 18% YoY (5% QoQ) in revenues partly driven by Rupee depreciation which is likely to be 4-5% of the overall growth.
KYI: Wrapping up 2011, what should you invest in 2012?

Know Your Investment, helps investors take a prudent call on their investments. This week, Hemang Mamtora, Vice President- Equity Advisory Desk, Emkay Global Financial Services Ltd gives his take on various sectors and stocks.

Divis Labs Mar qtr PAT seen down at Rs 104.8 cr: MOST

Motilal Oswal has come out with its earning estimates on Pharmaceuticals sector for the quarter ended March 2011. According to the research firm, Divis Labs March quarter sales are expected to go up by 0.3% at Rs 315.2 crore, year-on-year, (YoY) basis.
Divis Labs Dec qtr PAT seen up 31.1% at Rs 88.9cr: Karvy

Karvy Stock Broking has come out with its earning estimates on pharma sector for the quarter ended December 2010. According to the research firm, Divis Laboratories December quarter sales are expected to go up by 43.1% at Rs 292 crore, Year-on-Year, (YoY) basis.